Literature DB >> 16451135

Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study).

G Kurzawski1, J Suchy, M Lener, E Kłujszo-Grabowska, J Kładny, K Safranow, K Jakubowska, A Jakubowska, T Huzarski, T Byrski, T Debniak, C Cybulski, J Gronwald, O Oszurek, D Oszutowska, E Kowalska, S Góźdź, S Niepsuj, R Słomski, A Pławski, A Łacka-Wojciechowska, A Rozmiarek, Ł Fiszer-Maliszewska, M Bebenek, D Sorokin, M M Sasiadek, A Stembalska, Z Grzebieniak, E Kilar, M Stawicka, D Godlewski, P Richter, I Brozek, B Wysocka, J Limon, A Jawień, Z Banaszkiewicz, H Janiszewska, J Kowalczyk, D Czudowska, R J Scott, J Lubiński.   

Abstract

Germline mutations in the DNA mismatch repair genes MSH2 and MLH1 account for a significant proportion of hereditary non-polyposis colorectal cancer (HNPCC) families. One approach by which development of an efficient DNA-testing procedure can be implemented is to describe the nature and frequency of common mutations in particular ethnic groups. Two hundred and twenty-six patients from families matching the Amsterdam II diagnostic criteria or suspected HNPCC criteria were screened for MSH2 and MLH1 germline mutations. Fifty different pathogenic mutations were found, 25 in MSH2 and 25 in MLH1. Twenty-four of these had not previously been described in other populations. Among our 78 families with MSH2 or MLH1 mutations, 54 (69.2%) were affected by recurrent mutations including 38 found at least twice in our own series. Two of the most frequent alterations were a substitution of A to T at the splice donor site of intron 5 of MSH2 and a missense change (A681T) of MLH1 found in 10 and eight families, respectively. Among large deletions detected by the multiplex ligation-dependent probe amplification assay, exon 9 deletions in the MSH2 gene were found in two families. Our results indicate that a screening protocol specific for the Polish population that is limited to the detection of all reported mutations will result in the identification of the majority of changes present in MLH1 and MSH2 genes in Polish HNPCC kindreds.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16451135     DOI: 10.1111/j.1399-0004.2006.00550.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  16 in total

1.  Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients.

Authors:  Dagmara Dymerska; Pablo Serrano-Fernández; Janina Suchy; Andrzej Pławski; Ryszard Słomski; Krzysztof Kaklewski; Rodney J Scott; Jacek Gronwald; Józef Kładny; Tomasz Byrski; Tomasz Huzarski; Jan Lubiński; Grzegorz Kurzawski
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

2.  Some aspects of molecular diagnostics in Lynch syndrome.

Authors:  Grzegorz Kurzawski
Journal:  Hered Cancer Clin Pract       Date:  2006-12-15       Impact factor: 2.857

3.  Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers.

Authors:  Wenche Sjursen; Bjørn Ivar Haukanes; Eli Marie Grindedal; Harald Aarset; Astrid Stormorken; Lars F Engebretsen; Christoffer Jonsrud; Inga Bjørnevoll; Per Arne Andresen; Sarah Ariansen; Liss Anne S Lavik; Bodil Gilde; Inger Marie Bowitz-Lothe; Lovise Maehle; Pål Møller
Journal:  J Med Genet       Date:  2010-06-28       Impact factor: 6.318

4.  MLH1 promoter hypermethylation: are you absolutely sure about the absence of MLH1 germline mutation? About a new case.

Authors:  Caroline Kientz; Fabienne Prieur; Alix Clemenson; Marie-Odile Joly; Marie-Laure Stachowicz; Jessie Auclair; Valéry Attignon; Renaud Schiappa; Qing Wang
Journal:  Fam Cancer       Date:  2019-11-19       Impact factor: 2.375

5.  Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome.

Authors:  S Gargiulo; M Torrini; S Ollila; S Nasti; L Pastorino; R Cusano; L Bonelli; L Battistuzzi; L Mastracci; W Bruno; V Savarino; S Sciallero; G Borgonovo; M Nyström; G Bianchi-Scarrà; C Mareni; P Ghiorzo
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

6.  MSH2 and MLH1 testing.

Authors:  Grzegorz Kurzawski; Janina Suchy; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

7.  Colon cancer associated genes exhibit signatures of positive selection at functionally significant positions.

Authors:  Claire C Morgan; Kabita Shakya; Andrew Webb; Thomas A Walsh; Mark Lynch; Christine E Loscher; Heather J Ruskin; Mary J O'Connell
Journal:  BMC Evol Biol       Date:  2012-07-12       Impact factor: 3.260

8.  Recurrent APC gene mutations in Polish FAP families.

Authors:  Andrzej Pławski; Marta Podralska; Ryszard Słomski
Journal:  Hered Cancer Clin Pract       Date:  2007-12-15       Impact factor: 2.857

9.  Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers.

Authors:  Katarina Zavodna; Tomas Krivulcik; Maria Gerykova Bujalkova; Tomas Slamka; David Martinicky; Denisa Ilencikova; Zdena Bartosova
Journal:  BMC Cancer       Date:  2009-11-20       Impact factor: 4.430

10.  Prevalence of pathological germline mutations of hMLH1 and hMSH2 genes in colorectal cancer.

Authors:  Dandan Li; Fulan Hu; Fan Wang; Binbin Cui; Xinshu Dong; Wencui Zhang; Chunqing Lin; Xia Li; Da Wang; Yashuang Zhao
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.